How CAR T-Cell Therapy Impacts Relapsed/Refractory MM Treatment

Opinion
Video

Yi Lin, MD, PhD, provides insights on the impact of CAR T-cell therapy on the evolving multiple myeloma treatment landscape.

Video content above is prompted by the following questions:

  • What is the impact of CAR T-cell therapy on patient quality of life and how does it compare to other available treatments?
    • How do patients typically respond to CAR T-cell therapy in terms of their overall well-being and ability to perform daily activities?
    • Are there any long-term quality of life benefits or challenges associated with CAR T-cell therapy?
Recent Videos
4 experts are featured in this series.
3 experts in this video
3 experts in this video
3 experts in this video
3 experts in this video
3 experts in this video
3 experts in this video
3 experts in this video
3 experts in this video
Using bispecific antibodies before or after CAR T-cell therapy in multiple myeloma is an area of education for community oncologists.
Related Content